Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

No increase in protease resistance and a decrease in reverse transcriptase resistance mutations in primary HIV-1

Palanee Ammaranond1, Philip Cunningham, Robert Oelrichs

  • 1National Centre in HIV Epidemiology and Clinical Research, Sydney, NSW, Australia.

AIDS (London, England)
|January 25, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design and methods of the Third Australian Study of Health and Relationships (ASHR3): a nationally representative sexual and reproductive health survey.

Sexual health·2026
Same author

Effects of Increasing the Concentration of Dialysate Magnesium on Cardiovascular Health: A Narrative Review.

Canadian journal of kidney health and disease·2026
Same author

Inconsistencies in care: a UK and Ireland survey exploring acute vestibular service provision in adult major trauma centres.

Frontiers in neurology·2026
Same author

Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic risk.

Trials·2026
Same author

Comparison of immunity-boosting regimens for COVID-19 upon initiation of immunosuppressive therapy (CIRCUIT): study protocol for a randomised, controlled clinical trial.

BMJ open·2026
Same author

Comparative analysis of clinically approved lipid nanoparticles for intranasal siRNA delivery against SARS-CoV-2.

Drug delivery and translational research·2026
Same journal

Hazardous alcohol use, sexual behavior, and recent and undiagnosed HIV across 11 Eastern and Southern African countries.

AIDS (London, England)·2026
Same journal

Carotid inflammation on FDG-PET is associated with lower cognitive performance in people with treated HIV infection.

AIDS (London, England)·2026
Same journal

Clinical implications of the new definition of obesity among persons with HIV.

AIDS (London, England)·2026
Same journal

Cabotegravir and rilpivirine resistance-associated mutations among people with newly diagnosed HIV-1 in the Netherlands.

AIDS (London, England)·2026
Same journal

Pitavastatin effect on enterocyte injury markers in an ART treated HIV population: Insights from REPRIEVE.

AIDS (London, England)·2026
Same journal

Blood pressure control in people with HIV and established atherosclerotic cardiovascular disease: a real-world descriptive analysis.

AIDS (London, England)·2026
See all related articles

Antiretroviral resistance in Sydney has fluctuated but remains low. Combination therapy significantly reduced resistance rates, which have plateaued in recent years.

Area of Science:

  • Virology
  • Epidemiology
  • Public Health

Background:

  • Antiretroviral resistance in Sydney, Australia, has shown variable rates over the last decade.
  • Treatment trends have influenced the prevalence of drug resistance in newly transmitted HIV infections.

Discussion:

  • Rates of antiretroviral resistance in Sydney are not historically high and are comparable to other reported findings.
  • Resistance to reverse transcriptase inhibitors, after peaking in the mid-1990s, declined sharply with the advent of combination therapy.
  • Current resistance rates to reverse transcriptase inhibitors have stabilized between 10-15% over the last three years.

Key Insights:

  • The introduction of combination antiretroviral therapy has been effective in curbing the rise of drug resistance.
  • Primary resistance mutations within the protease gene remain infrequent in the studied population.

Related Experiment Videos

  • The current level of antiretroviral resistance in Sydney does not pose a significant public health concern in historical or comparative contexts.

    • Outlook:

    • Continued monitoring of resistance patterns is essential to guide future treatment strategies.
    • Sustained effectiveness of combination therapy suggests a stable outlook for managing HIV drug resistance.
    • Further research may explore the specific factors contributing to the plateaued resistance rates.